Orphan Drug Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Orphan Drug stocks.

Orphan Drug Stocks Recent News

Date Stock Title
May 17 CYTK Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself
May 17 CYTK Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
May 16 AVBP ArriVent Appoints John Hohneker, M.D., to its Board of Directors
May 15 GMAB Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
May 15 RGEN Here’s Why Baron Discovery Fund Sold Repligen Corporation (RGEN)
May 15 CYTK Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
May 14 AVTE Aerovate Therapeutics reports Q1 GAAP EPS of -$0.83
May 14 GMAB Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14 PLRX Pliant reports phase 2 data on idiopathic pulmonary fibrosis asset bexotegrast
May 14 PLRX Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
May 14 GMAB Danish biotech says companies should tap into China’s ‘impressive innovation’
May 13 CYTK Health Care Roundup: Market Talk
May 13 AVTE Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 13 CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Orphan Drug

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.In the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.

Browse All Tags